Milivojevic M, Boskovic V, Atanackovic J, Milicevic S, Razic S, Kotlica B Kastratovic
Center of Medical Biochemistry, Clinical Center of Serbia, Belgrade, Serbia.
Eur J Gynaecol Oncol. 2013;34(1):83-5.
The objective of this study was to determine the potential of osteopontin (OPN) and OPN + CA125 (cancer antigen 125) combination in differential diagnosis of the ovarian cancers and non-malignant ovarian disease. Serum and plasma samples were obtained preoperatively from 79 women undergoing surgery for pelvic mass; 48 of them had ovarian carcinoma, and 31 had benign cyst. The samples were analyzed for the levels of OPN and CA 125 (using ELISA and CMIA methods) and then compared with the final pathologic results. The median plasma level of OPN in patients with benign and malignant cysts was 356.33 ng/ml and 865.15 ng/ml, respectively (p < 0.001). Receiver operating characteristic (ROC) analysis for plasma OPN revealed the area under the curve (AUC) of 0.838. At the predefined specificity of 90%, OPN showed sensitivity of 62.5%, whereas the combination of OPN + CA125 reached 74.9% at the same specificity.
本研究的目的是确定骨桥蛋白（OPN）以及OPN与癌抗原125（CA125）联合检测在卵巢癌与非恶性卵巢疾病鉴别诊断中的潜力。术前从79例因盆腔肿块接受手术的女性中获取血清和血浆样本；其中48例患有卵巢癌，31例患有良性囊肿。分析样本中OPN和CA125的水平（采用酶联免疫吸附测定法和化学发光微粒子免疫分析法），然后与最终病理结果进行比较。良性和恶性囊肿患者血浆中OPN的中位数水平分别为356.33 ng/ml和865.15 ng/ml（p < 0.001）。血浆OPN的受试者工作特征（ROC）分析显示曲线下面积（AUC）为0.838。在预定义的90%特异性下，OPN的灵敏度为62.5%，而在相同特异性下，OPN与CA125联合检测的灵敏度达到74.9%。
